

Natural History of Bronchiectasis

NCT00943514

Status	RECRUITING
Sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Enrollment	900 participants

Key Eligibility Criteria

Inclusion (6)

- Children age 5 years and above and adults referred to the NIH with chronic or recurring respiratory infections will be eligible for participation.
 - Males and females will be considered without regard to race or ethnicity or upper age limit.
 - Emphasis will be primarily on non CF bronchiectasis for elucidation of mechanisms of infection susceptibility. However, select patients with cystic fibrosis or acquired immune defects (such as HIV) may be studied if relevant host defects are suspected, if needed for comparison purposes, or to evaluate and study the management of chronic pathogen associated conditions such as nontuberculous mycobacterial infections or allergic bronchopulmonary aspergillosis.
 - Subjects must have a primary or referring physician
 - Subjects must be willing to have samples stored
- ... and 1 more (see full listing online)

Exclusion (5)

- We wish to avoid enrolling subjects, especially children, who have common respiratory problems (aeroallergen sensitivity, asthma, gastric esophageal reflux) that are not associated with an underlying abnormality in host defenses. Evidence of significance of chronic or recurring infections suggestive of an underlying airway surface or systemic host defense defect should be documented by one or more of the following: a) sinus or lower airway cultures positive for bacterial, fungal, or mycobacterial pathogens characteristic of these defects; or b) radiographic evidence of sinusitis with mucosal thickening and/or air-fluid levels; or c) radiographic evidence of bronchiectasis; d) severity of otitis media requiring placement of tympanic membrane pressure equalization tubes; e) severity of sinusitis requiring surgical intervention.
- Patients who are unable or unwilling to provide informed consent either directly or via appropriately designated surrogate.
- Any patient who, in the opinion of the Investigator, is unable or unwilling to comply with regular follow-up or is unlikely to provide pertinent information regarding disease progression or response to treatment may be excluded from longitudinal follow-up.
- PARTICIPATION OF CHILDREN:
 - Children under the age of 5 will be excluded from this protocol due to the difficulty of performing pertinent assays in infants and younger children, difficulty distinguishing significance of respiratory infections which occur commonly in younger children, and the lack of adequate facilities and equipment for management of children younger than 2 years.

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

<https://clinicaltrials.gov/study/NCT00943514>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).